The Ultimate Guide To Digitizing Cell And Gene Therapy Manufacturing

Cell and gene therapy manufacturers are operating in a market defined by rapid scientific progress but limited production capacity. With the majority of manufacturing outsourced and commercial demand projected to exceed current capabilities by more than tenfold, organizations must rethink how they scale from clinical to commercial supply. Digital transformation is emerging as a critical enabler, offering a path to eliminate manual bottlenecks, strengthen compliance, and accelerate the delivery of personalized therapies.

Explore practical ways to overcome scalability barriers, from reducing batch review times by up to 80% to managing the complexities of individualized “batch‑of‑one” workflows.